DK1154764T3 - Anvendelse af epoxidhyrolasekomplekser til behandling af hypertension - Google Patents
Anvendelse af epoxidhyrolasekomplekser til behandling af hypertensionInfo
- Publication number
- DK1154764T3 DK1154764T3 DK00911767T DK00911767T DK1154764T3 DK 1154764 T3 DK1154764 T3 DK 1154764T3 DK 00911767 T DK00911767 T DK 00911767T DK 00911767 T DK00911767 T DK 00911767T DK 1154764 T3 DK1154764 T3 DK 1154764T3
- Authority
- DK
- Denmark
- Prior art keywords
- epoxide
- sulfur
- oxygen
- hydrogen
- nitrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/252,148 US6150415A (en) | 1996-08-13 | 1999-02-18 | Epoxide hydrolase complexes and methods therewith |
PCT/US2000/003495 WO2000048593A1 (fr) | 1999-02-18 | 2000-02-10 | Complexes d'epoxyde hydrolases et methodes associees |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1154764T3 true DK1154764T3 (da) | 2008-02-04 |
Family
ID=22954799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00911767T DK1154764T3 (da) | 1999-02-18 | 2000-02-10 | Anvendelse af epoxidhyrolasekomplekser til behandling af hypertension |
Country Status (10)
Country | Link |
---|---|
US (1) | US6150415A (fr) |
EP (2) | EP1154764B1 (fr) |
JP (1) | JP2002540767A (fr) |
AT (1) | ATE375153T1 (fr) |
AU (1) | AU3360800A (fr) |
CA (1) | CA2362331C (fr) |
DE (1) | DE60036690T2 (fr) |
DK (1) | DK1154764T3 (fr) |
ES (1) | ES2291196T3 (fr) |
WO (1) | WO2000048593A1 (fr) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2000042012A1 (fr) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | DIPHENYLUREES A SUBSTITUANTS φ-CARBOXYARYLES, INHIBITRICES DE KINASE RAF |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US6831099B1 (en) * | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US6562563B1 (en) * | 1999-11-03 | 2003-05-13 | Mitokor | Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2002082082A2 (fr) * | 2001-04-09 | 2002-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Analyse par polarisation de fluorescence |
US6756210B2 (en) * | 2001-05-29 | 2004-06-29 | The Regents Of The University Of California | Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids |
CA2456229A1 (fr) * | 2001-08-03 | 2003-02-13 | Diversa Corporation | Epoxyde-hydrolases, acides nucleiques codant ces hydrolases et procedes de fabrication et d'utilisation de celles-ci |
US6943001B2 (en) * | 2001-08-03 | 2005-09-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
US20030139469A1 (en) * | 2002-01-23 | 2003-07-24 | The Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
PT1478358E (pt) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
ES2378670T3 (es) | 2002-02-11 | 2012-04-16 | Bayer Healthcare, Llc | Aril ureas como inhibidores de cinasas |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
GB0214342D0 (en) * | 2002-06-21 | 2002-07-31 | Givaudan Sa | Insect repellents |
UA80841C2 (en) | 2002-10-07 | 2007-11-12 | Univ California | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
JP4943837B2 (ja) * | 2003-04-03 | 2012-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良インヒビター |
US20050164951A1 (en) * | 2003-04-03 | 2005-07-28 | The Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
CA2526617C (fr) | 2003-05-20 | 2015-04-28 | Bayer Pharmaceuticals Corporation | Diaryl-urees presentant une activite d'inhibition des kinases |
AU2004259760B9 (en) | 2003-07-23 | 2011-02-03 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
JP2007532484A (ja) | 2004-03-16 | 2007-11-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法 |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
WO2006045119A2 (fr) * | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Inhibiteurs ameliores de l'epoxyde hydrolase soluble |
CA2608243A1 (fr) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Methodes d'utilisation d'acylhydrazones comme inhibiteurs de seh |
WO2006121719A2 (fr) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International, Gmbh | Inhibiteurs de l'epoxyde hydrolase soluble et leurs methodes d'utilisation |
US9119837B2 (en) * | 2005-08-19 | 2015-09-01 | The Regents Of The University Of California | Use of sEH inhibitors as analgesics |
CA2622754A1 (fr) * | 2005-10-07 | 2007-04-19 | Boehringer Ingelheim International Gmbh | Composes de pyridinone ou pyrimidinone n-substitues utiles en tant qu'inhibiteurs d'epoxyde hydrolase soluble |
CN105237621A (zh) | 2005-11-09 | 2016-01-13 | 欧尼斯治疗公司 | 用于酶抑制的化合物 |
CA2636601C (fr) * | 2006-01-13 | 2019-03-19 | Mcgill University | Nouveaux ligands de type melatonine presentant une activite d'antidepresseurs ainsi que des proprietes somniferes |
US20090111791A1 (en) * | 2006-03-10 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same |
TW200808723A (en) | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
MX2008016512A (es) | 2006-06-19 | 2009-02-26 | Proteolix Inc | Epoxicetonas peptidicas para la inhibicion del proteasoma. |
WO2008073130A1 (fr) * | 2006-12-15 | 2008-06-19 | Regents Of The University Of California | Utilisation d'acides cis-époxyeicosatriénoïques et inhibiteurs de l'époxyde hydrolase soluble pour traiter les affections dont les récepteurs pbr, cb2, et nk2 sont en cause |
CN101563088A (zh) * | 2006-12-18 | 2009-10-21 | 弗·哈夫曼-拉罗切有限公司 | 可溶性环氧化物水解酶的抑制剂的新用途 |
EP2178534A4 (fr) * | 2007-07-17 | 2011-03-30 | Merck Sharp & Dohme | Inhibiteurs époxyde hydrolase solubles, compositions contenant de tels composés et procédés de traitement |
US20110098322A1 (en) * | 2007-08-06 | 2011-04-28 | The Regents Of The University Of California | Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase |
CL2008002966A1 (es) | 2007-10-04 | 2010-06-25 | Onyx Therapeutics Inc | Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros. |
WO2009111207A1 (fr) * | 2008-03-04 | 2009-09-11 | Merck & Co., Inc. | Inhibiteurs de l'époxyde hydrolase solubles, compositions contenant ces composés et procédés de traitement |
EP2100598A1 (fr) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques |
EP2100599A1 (fr) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
WO2010096722A1 (fr) | 2009-02-20 | 2010-08-26 | Takeda Pharmaceutical Company Limited | 3-oxo-2,3-dihydro-[1,2,4]triazolo[4, 3-a]pyridines utilisées comme inhibiteurs de l'époxyde hydrolase soluble (eh soluble) |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
US9296693B2 (en) | 2010-01-29 | 2016-03-29 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
EA201290844A1 (ru) | 2010-03-01 | 2013-03-29 | Оникс Терапьютикс, Инк. | Соединения для ингибирования иммунопротеасом |
KR20130094185A (ko) | 2010-04-07 | 2013-08-23 | 오닉스 세라퓨틱스, 인크. | 결정성 펩티드 에폭시케톤 면역프로테아좀 저해제 |
EP2389922A1 (fr) | 2010-05-25 | 2011-11-30 | Symrise AG | Composés de carbamate de cyclohexyle en tant qu'actifs anti-vieillissements |
EP2675274B1 (fr) | 2011-02-14 | 2017-05-03 | The Regents of The University of California | DÉRIVÉS DE SORAFÉNIB UTILISÉS EN TANT QU'INHIBITEURS DE LA sEH |
EP2510928A1 (fr) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires |
CN104093708B (zh) | 2012-02-01 | 2016-11-09 | 加利福尼亚大学董事会 | 可溶性环氧化物水解酶的酰基哌啶抑制剂 |
US10383835B2 (en) | 2012-03-14 | 2019-08-20 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
EP2869820A4 (fr) | 2012-07-09 | 2016-02-17 | Onyx Therapeutics Inc | Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique |
WO2016133788A1 (fr) | 2015-02-20 | 2016-08-25 | The Regents Of The University Of California | Méthodes d'inhibition de la douleur |
US20200317813A1 (en) | 2016-05-25 | 2020-10-08 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Treatment and diagnosis of non-proliferative diabetic retinopathy |
US20210378995A1 (en) | 2018-10-10 | 2021-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1056290A (en) * | 1963-05-06 | 1967-01-25 | Du Pont | Dicycloalkyl ureas |
CA2017383A1 (fr) * | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Utilisation de vanilloides pour le traitement des affections ou des troubles respiratoires |
CA2036770C (fr) * | 1990-02-26 | 2003-09-09 | Jeffrey P. Whitten | Inhibiteurs de la biosynthese de l'oxyde nitrique |
US5445956A (en) * | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
US5599984A (en) * | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
JP2909620B2 (ja) * | 1995-03-07 | 1999-06-23 | 参天製薬株式会社 | N,n−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体 |
US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US5955496A (en) * | 1996-08-13 | 1999-09-21 | The Regents Of The University Of California | Dihydroxy-oxy-eicosadienoates |
-
1999
- 1999-02-18 US US09/252,148 patent/US6150415A/en not_active Expired - Lifetime
-
2000
- 2000-02-10 WO PCT/US2000/003495 patent/WO2000048593A1/fr active IP Right Grant
- 2000-02-10 AU AU33608/00A patent/AU3360800A/en not_active Abandoned
- 2000-02-10 AT AT00911767T patent/ATE375153T1/de active
- 2000-02-10 DK DK00911767T patent/DK1154764T3/da active
- 2000-02-10 EP EP00911767A patent/EP1154764B1/fr not_active Expired - Lifetime
- 2000-02-10 DE DE60036690T patent/DE60036690T2/de not_active Expired - Lifetime
- 2000-02-10 EP EP07014966A patent/EP1844767B1/fr not_active Expired - Lifetime
- 2000-02-10 CA CA2362331A patent/CA2362331C/fr not_active Expired - Fee Related
- 2000-02-10 ES ES00911767T patent/ES2291196T3/es not_active Expired - Lifetime
- 2000-02-10 JP JP2000599385A patent/JP2002540767A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2000048593A1 (fr) | 2000-08-24 |
ATE375153T1 (de) | 2007-10-15 |
EP1844767A3 (fr) | 2010-01-13 |
US6150415A (en) | 2000-11-21 |
ES2291196T3 (es) | 2008-03-01 |
EP1154764A4 (fr) | 2005-02-16 |
DE60036690T2 (de) | 2008-07-17 |
JP2002540767A (ja) | 2002-12-03 |
CA2362331A1 (fr) | 2000-08-24 |
EP1844767B1 (fr) | 2012-08-29 |
EP1844767A2 (fr) | 2007-10-17 |
AU3360800A (en) | 2000-09-04 |
DE60036690D1 (de) | 2007-11-22 |
EP1154764B1 (fr) | 2007-10-10 |
CA2362331C (fr) | 2010-04-20 |
EP1154764A1 (fr) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1154764T3 (da) | Anvendelse af epoxidhyrolasekomplekser til behandling af hypertension | |
NZ505968A (en) | Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases | |
NO953305L (no) | Antranilsyrederivat | |
TR200402157T2 (tr) | Heteroaril süksinamidler ve metalloproteinaz inhibitörü olarak kullanımları | |
PT1178967E (pt) | Derivados de quinolina como inibidores de enzimas mek | |
ES2196396T3 (es) | Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. | |
AU3053999A (en) | Nitrogenous heterocyclic compounds | |
DE69613139D1 (de) | Heterozyclische fungizide | |
DE68906183D1 (de) | 2'-desoxy-5-fluoruridinderivate. | |
DE69332792T2 (de) | 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide | |
ES2164164T3 (es) | Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa. | |
PT1280809E (pt) | Derivados antitumorais de ecteinascidina | |
BR9508901A (pt) | Di-hidrobenzofurano e composto relacionados utilizáveis como agentes antiflamatórios | |
PH19684A (en) | Biologically acitve heterocyclic compounds | |
DE69911935D1 (de) | Granulatimide-derivate zur behandlung von krebs | |
NO873650D0 (no) | Dihydropyridinderivater. | |
ATE247660T1 (de) | Furopyridinderivate und ihre therapeutische verwendung | |
HK1028028A1 (en) | Substituted heterocyclic compounds, method for preparing and compositions containing same | |
ATE241976T1 (de) | N,n'-bis (sulfonyl) hydrazine die als antineoplastische mittel nützlich sind | |
ATE278678T1 (de) | Substituierte 1-aza-2-imino-heterocyclen und ihre verwendung als aktivatoren der nikotinergen acetylcholinrezeptoren | |
BR9707321A (pt) | Dihidrobenzofurano e compostor correlatos úteis como agentes antinflamatórios | |
MY121785A (en) | Hydroxamic acid derivatives as inhibitors of the production of soluble cd23 | |
BR0110328A (pt) | Compostos heterocìclicos com atividade antiinflamatória | |
AP2001002321A0 (en) | Aromatic amides. |